21:52 , Oct 5, 2018 |  BC Extra  |  Preclinical News

Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

Selecta Biosciences Inc. (NASDAQ:SELB) showed its SVP-Rapamycin nanoparticles co-administered with an adeno-associated viral (AAV) vector-mediated transgene could enable repeat dosing of a gene therapy by suppressing the host’s immune response against the viral vector in...
20:33 , Oct 5, 2018 |  BC Week In Review  |  Company News

Janssen terminates licenses to Aduro cancer therapies

Aduro BioTech Inc. (NASDAQ:ADRO) revealed in an SEC filing that the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) will terminate its licenses for three cancer therapies, effective Dec. 24. A Janssen spokesperson told...
15:36 , Jul 27, 2018 |  BC Week In Review  |  Company News

Sobi grabs Emapalumab, anticipates 2018 approval

Swedish Orphan Biovitrum AB (SSE:SOBI) received exclusive, worldwide rights from Novimmune S.A. (Plan-les-Ouates, Switzerland) to hematology candidate emapalumab (NI-0501). Novimmune will receive SEK450 million ($50.8 million) up front in cash, plus SEK3.6 billion ($406.5 million)...
22:11 , Jul 20, 2018 |  BC Extra  |  Company News

Sobi grabs emapalumab, anticipates 2018 approval

Swedish Orphan Biovitrum AB (SSE:SOBI) received exclusive, worldwide rights from Novimmune S.A. (Plan-les-Ouates, Switzerland) to hematology candidate emapalumab (NI-0501). Novimmune will receive SEK450 million ($50.8 million) up front in cash, plus SEK3.6 billion ($406.5 million)...
02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
22:52 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; cervical cancer; gastric cancer; lung cancer; pancreatic cancer Cell culture and mouse studies suggest three mesothelin-targeting chimeric immunotoxins could help treat mesothelin-expressing cancers. The three immunotoxins consist of the variable region a mouse...
15:46 , Mar 28, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy CAR T cells engineered to express IL-7 and CCL19 could enhance the efficacy of T cell therapies for cancer. The method involves engineering solid tumor antigen-targeting CAR T cells, dubbed proliferation-inducing and...
17:48 , Mar 23, 2018 |  BC Week In Review  |  Financial News

TCR2 raises $125M series B

TCR2 Therapeutics Inc. (Cambridge, Mass.) raised an untranched $125 million series B round on March 21 led by 6 Dimensions Capital and Curative Ventures and joined by fellow new investors Redmile Group, ArrowMark Partners, Hillhouse...
23:26 , Mar 21, 2018 |  BioCentury  |  Finance

Seeking domestic partners

The syndicate behind TCR2 Therapeutics Inc.’s $125 million series B round includes a bevy of Chinese investors who could provide access to development and manufacturing partners in China. 6 Dimensions Capital and Curative Ventures led...
12:00 , Mar 21, 2018 |  BC Extra  |  Financial News

TCR2 raises $125M series B

TCR2 Therapeutics Inc. (Cambridge, Mass.) raised an untranched $125 million series B round led by 6 Dimensions Capital and Curative Ventures and joined by fellow new investors Redmile Group, ArrowMark Partners, Hillhouse Capital, MiraeAsset Financial...